胰腺癌细胞-施旺细胞旁分泌TIMP1/CCL7协同促进肿瘤神经转移的研究

批准号:
81972741
项目类别:
面上项目
资助金额:
55.0 万元
负责人:
陈茵婷
依托单位:
学科分类:
肿瘤复发与转移
结题年份:
2023
批准年份:
2019
项目状态:
已结题
项目参与者:
陈茵婷
国基评审专家1V1指导 中标率高出同行96.8%
结合最新热点,提供专业选题建议
深度指导申报书撰写,确保创新可行
指导项目中标800+,快速提高中标率
微信扫码咨询
中文摘要
胰腺癌易发生神经转移而机制未明。我们在鼠坐骨神经胰腺癌浸润模型和背根神经节三维培养实验发现,神经纤维表面包绕的施旺细胞促进癌细胞神经转移;进一步预实验显示芯片筛选差异细胞因子中的TIMP1/CCL7是沟通胰腺癌细胞-施旺细胞关键因子、协同促进癌细胞迁移和侵袭。本课题拟进一步研究胰腺癌细胞通过TIMP1/PI3K/AKT激活施旺细胞促进神经重构以及施旺细胞通过CCL7/TIMP1/TWIST1促进胰腺癌向神经趋化的作用。建立转基因鼠模型验证胰腺细胞恶变进程TIMP1激活施旺细胞、推动神经侵犯作用;利用鼠坐骨神经胰腺癌浸润模型和课题组纳米技术验证上述旁分泌及示踪肿瘤神经转移,并联合负载shTIMP1和吉西他滨纳米微粒阻断旁分泌TIMP1及增敏吉西他滨、抑制肿瘤神经转移。最后,结合血清TIMP1、CCL7和临床各指标建立胰腺癌神经转移预测模型。本项目为胰腺癌神经转移诊断、治疗及预后提供新的思路。
英文摘要
The mechanism of neural metastasis in pancreatic cancer is unknown. We demonstrated that Schwann cells, wrapping on the surface of nerve fibers, significantly promoted pancreatic cancer cell metastasis to the nerve both in the mouse model of ischial nerve infiltration in vivo and in the three-dimensional culture model of dorsal root ganglion in vitro. We screened out TIMP1 and CCL7 by Cytokine Antibody Array Assay. In the following experiments we found that TIMP1 secreted by pancreatic cancer cells activated Schwann cells. Moreover, activated Schwann cells secreted CCL7 to promote the migration and invasion of cancer cells and up-regulate the expression of TIMP1 in pancreatic cancer cells. So we hypothesized that TIMP1/CCL7 are the key molecules to communicate with pancreatic cancer cells and Schwann cells. In order to elucidate the key pathways involved in neural metastasis of pancreatic cancer, we intend to investigate the specific mechanism that pancreatic cancer cells activate Schwann cells and promote nerve remodeling through TIMP1/PI3K/AKT, while Schwann cells promote nerve chemotactic of pancreatic cancer through CCL7/TIMP1/TWIST1. A transgenic mouse model will be established to verify that TIMP1 can activate Schwann cells and promote nerve invasion during the development of pancreatic cancer. The above paracrine loop and the tumor neural metastasis will be identified by the mouse model of ischial nerve infiltration and our established tracing nanotechnology. Then we plan to design immuno-nanoparticles loading shTIMP1 and gemcitabine to block the loop, increase the efficacy of gemcitabine and inhibit tumor nerve metastasis. Finally, based on the results of this study and some clinical indicators, we will establish a model for the prediction of pancreatic cancer neural metastasis. Overall, this study aims at providing new ideas and potential targets for the diagnosis, treatment and prognosis of pancreatic cancer neural metastasis.
期刊论文列表
专著列表
科研奖励列表
会议论文列表
专利列表
DOI:10.1016/j.trsl.2022.11.007
发表时间:2022-11
期刊:Translational research : the journal of laboratory and clinical medicine
影响因子:--
作者:Zhenfeng Tian;Ying Tan;Xingyi Lin;Mingxin Su;Lele Pan;Lijun Lin;Guang-sheng Ou;Yinting Chen
通讯作者:Zhenfeng Tian;Ying Tan;Xingyi Lin;Mingxin Su;Lele Pan;Lijun Lin;Guang-sheng Ou;Yinting Chen
DOI:--
发表时间:2022
期刊:岭南现代临床外科
影响因子:--
作者:林杏仪;田振烽;潘乐乐;苏铭昕;陈茵婷
通讯作者:陈茵婷
DOI:10.1007/s00280-023-04616-6
发表时间:2023-12-01
期刊:CANCER CHEMOTHERAPY AND PHARMACOLOGY
影响因子:3
作者:Lin,Xingyi;Tan,Ying;Chen,Yinting
通讯作者:Chen,Yinting
DOI:10.1016/j.canlet.2022.215863
发表时间:2022-08
期刊:Cancer letters
影响因子:9.7
作者:Zhenfeng Tian;Guang-sheng Ou;Mingxin Su;Ruomeng Li;Lele Pan;Xingyi Lin;Jinmao Zou;Shangxiang Chen;Ya-qing Li;Kaihong Huang;Yinting Chen
通讯作者:Zhenfeng Tian;Guang-sheng Ou;Mingxin Su;Ruomeng Li;Lele Pan;Xingyi Lin;Jinmao Zou;Shangxiang Chen;Ya-qing Li;Kaihong Huang;Yinting Chen
Nanoparticles modified by triple single chain antibodies for MRI examination and targeted therapy in pancreatic cancer
三重单链抗体修饰的纳米颗粒用于胰腺癌的 MRI 检查和靶向治疗。
DOI:10.1039/c9nr04976b
发表时间:2020
期刊:Nanoscale
影响因子:6.7
作者:Jinmao Zou;Shangxiang Chen;Yaqing Li;Linjuan Zeng;Guoda Lian;Jiajia Li;Shaojie Chen;Kaihong Huang;Yinting Chen
通讯作者:Yinting Chen
胰腺癌吉西他滨耐药细胞外泌体linc-ZNF25-1促进胰腺星状细胞摄取天冬酰胺推进化疗抵抗
- 批准号:--
- 项目类别:省市级项目
- 资助金额:15.0万元
- 批准年份:2024
- 负责人:陈茵婷
- 依托单位:
胰腺癌细胞-施旺细胞经谷氨酰胺-谷氨酸代谢环路促进肿瘤周围神经浸润
- 批准号:82273409
- 项目类别:面上项目
- 资助金额:52万元
- 批准年份:2022
- 负责人:陈茵婷
- 依托单位:
三氧化二砷逆转吉西他滨化疗抵抗及载双药纳米微粒靶向治疗胰腺癌研究
- 批准号:2020A151501341
- 项目类别:省市级项目
- 资助金额:10.0万元
- 批准年份:2020
- 负责人:陈茵婷
- 依托单位:
KRAS/ERK/RKIP通路在胰腺癌化疗抵抗中的作用及载砷纳米微粒的靶向调控
- 批准号:81672408
- 项目类别:面上项目
- 资助金额:57.0万元
- 批准年份:2016
- 负责人:陈茵婷
- 依托单位:
Bmi-1通过miR-27a调控RKIP促进胃癌EMT和化疗耐药的机制研究
- 批准号:81302140
- 项目类别:青年科学基金项目
- 资助金额:23.0万元
- 批准年份:2013
- 负责人:陈茵婷
- 依托单位:
国内基金
海外基金
